Clinical Trials in Woolloongabba, Australia, 2026

Trials with a site in Woolloongabba

Status

Study

Lead sponsor

Phase

Enrol

Sites in Australia

Start

Not yet open

Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT07634289Relapsed /Refractory DLBCL

DrugsGlofitamab·Obinutuzumab

Olivia Newton-John Cancer Research Institute

Phase 2

Douglas, Woolloongabba, Bedford Park, Heidelberg, Murdoch

2026-12

Recruiting

Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study

NCT07746895C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

DrugPegcetacoplan

Swedish Orphan Biovitrum

Phase 4

150

Kingswood, Woolloongabba

2026-08-05

Recruiting

Safety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) Nephropathy

NCT07606352IgAN

DrugSTL303

Sitala Bio LTD

Phase 2

Newcastle, Penrith, Sydney, Woolloongabba, Clayton, Saint Albans, Perth

2026-08-04

Recruiting

The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma

NCT07565285Melanoma Stage III

DrugPembrolizumab

Primmune Therapeutics, Inc.

Phase 2

Waratah, Cairns, Greenslopes, Woolloongabba, Melbourne, Nedlands

2026-07-01

Recruiting

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

NCT07224672Amyloidosis

DrugsBelantamab mafodotin·Bortezomib·Dexamethasone·Cyclophosphamide

GlaxoSmithKline

Phase 2

Westmead, Woolloongabba, Box Hill, Frankston

2026-06-24

Recruiting

A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

NCT07554339Non-small Cell Lung Cancer

DrugsCalderasib·Durvalumab

Merck Sharp & Dohme LLC

Phase 3

310

Frenchs Forest, Woolloongabba, Frankston

2026-06-18

Recruiting

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07562152Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

Immuneering Corporation

Phase 3

510

Kingswood, Waratah, Chermside, Woolloongabba, Adelaide, Frankston East

2026-06-05

Recruiting

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

NCT07517263Cardiovascular Disease and Lipoprotein(a)

DrugPelacarsen

Novartis Pharmaceuticals

Phase 3

5,700

Camperdown, Liverpool, Chemside, Woolloongabba, Clayton, Perth

2026-05-11

Not yet open

Vaccination Response Modulation With a Targeted Rapamycin Protocol Study

NCT07587801Vaccine Immune Response, Haemodialysis Patients, Older Adults

DrugsRSV Vaccine·Influenza vaccine·Rapamycin·Sirolimus

Central Adelaide Local Health Network Incorporated

Phase 2

Camperdown, Woolloongabba, Adelaide

2026-05

Active, closed

Contralateral Claims Study of Clareon Vivity Pro

NCT07484191Aphakia, Presbyopia

Alcon Research

Not applicable

165

Campsie, Sydney, Wollongong, Woolloongabba, East Melbourne, Mornington

2026-04-28

Recruiting

EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

NCT07287670Diffuse Cutaneous Systemic Sclerosis

Mediar Therapeutics

Phase 2

Southport, Woolloongabba, Heidelberg

2026-04-16

Recruiting

A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

NCT07489495Carcinoma, Renal Cell

DrugsZanzalintinib·Belzutifan

Merck Sharp & Dohme LLC

Phase 3

758

Macquarie University, Woolloongabba, Melbourne

2026-04-09

Recruiting

A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab

NCT07391670Solid Tumours

DrugsTremelimumab·Durvalumab

AstraZeneca

Phase 1

Fitzroy, St Albans, Woolloongabba

2026-03-31

Recruiting

PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease

NCT07355296Proteinuric Kidney Diseases

DrugApecotrep

Boehringer Ingelheim

Phase 2

132

Concord, Kingswood, New Lambton Heights, Brisbane, Woolloongabba

2026-03-23

Recruiting

MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

NCT07431827Non-small Cell Lung Cancer

DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Calderasib

Merck Sharp & Dohme LLC

Phase 3

400

Frenchs Forest, Woolloongabba, Frankston

2026-03-18

Recruiting

BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System

NCT07118358Leadless Pacemaker, Bradycardia, AV Block, Cardiac Rhythm Disorder

Biotronik, Inc.

Not applicable

325

Woolloongabba, Adelaide, Clayton

2026-03-16

Recruiting

A Multicenter Randomized Controlled Trial to Treat Acute T Cell Mediated Rejection in Kidney and Kidney-Pancreas Transplant Recipients

NCT06474273Rejection; Transplant, Kidney, Rejection; Transplant, Pancreas

DrugsMethylprednisolone·Prednisone

University of Sydney

Phase 3

540

Lambton, Randwick, Westmead, South Brisbane, Woolloongabba, Adelaide, Clayton, Murdoch

2026-03-13

Recruiting

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

NCT07284849CRC (Colorectal Cancer)

DrugsINCA33890·Folfox·Bevacizumab

Incyte Corporation

Phase 3

700

Port Macquarie, Randwick, Waratah, Westmead, Wollongong, Southport, Townsville, Woolloongabba

2026-03-05

Recruiting

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer

DrugsSonesitatug Vedotin·Zolbetuximab·Rilvegostomig·Leucovorin

AstraZeneca

Phase 3

2,130

Darlinghurst, Garran, Heidelberg, Murdoch, Randwick, Westmead, Woolloongabba

2026-02-03

Recruiting

TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

NCT07223203Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN

DrugsNucresiran·Vutrisiran

Alnylam Pharmaceuticals

Phase 3

125

Darlinghurst, Woolloongabba

2026-02-03

Recruiting

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

NCT07277231Chronic Lymphocytic Leukemia

DrugsSonrotoclax·Venclyxto·Acalabrutinib·Venclexta

BeOne Medicines

Phase 3

500

Blacktown, Concord, St Leonards, Woolloongabba, Clayton, Heidelberg, Malvern, Melbourne

2026-01-22

Recruiting

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

NCT07195695Non-small Cell Lung Cancer

DrugsZongertinib·Atezolizumab·Durvalumab·Nivolumab

Boehringer Ingelheim

Phase 3

400

Bedford Park, Subiaco, Heidelberg, Sydney, Woolloongabba

2026-01-16

Recruiting

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

NCT07195916Solid Tumors, Hematologic Malignancies

Incyte Corporation

Phase 1

280

Sydney, Woolloongabba, Adelaide, Melbourne

2026-01-08

Recruiting

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

NCT07104565Immune Thrombocytopenia

Incyte Corporation

Phase 2

Darlinghurst, Douglas, Woolloongabba, Box Hill, Clayton, Melbourne

2025-12-29

Recruiting

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT07225946Prostatic Neoplasms, Castration-Resistant

DrugsPasritamig·Prednisone/Prednisolone·Docetaxel

Janssen Research & Development, LLC

Phase 3

800

Heidelberg, Kurralta Park, Melbourne, Wahroonga, Woolloongabba

2025-12-19

Recruiting

A Feasibility Study Implant of the WiSE® CRT System With an Intracardiac Pacemaker to Achieve Totally Leadless CRT

NCT06561932Heart Failure

EBR Systems, Inc.

Not applicable

Birtinya, Herston, Southport, Woolloongabba

2025-12-18

Recruiting

A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

NCT07221474Squamous Non-small Cell Lung Cancer

DrugsIntismeran autogene·Nab-paclitaxel·Keytruda·Paclitaxel

Merck Sharp & Dohme LLC

Phase 2

180

Westmead, Woolloongabba, Nedlands

2025-12-12

Recruiting

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

NCT07221188Non-alcoholic Fatty Liver Disease

DrugEfimosfermin alfa

GlaxoSmithKline

Phase 3

1,250

Woolloongabba

2025-12-12

Recruiting

A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia

NCT07144163Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia

DrugAtumelnant

Crinetics Pharmaceuticals Inc.

Phase 3

150

Herston, Woolloongabba, Adelaide, Parkville, Nedlands

2025-12-11

Recruiting

A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis

NCT07235384Atopic Dermatitis (AD)

Zai Lab (Shanghai) Co., Ltd.

Phase 1

Woolloongabba, Carlton

2025-12-01

Recruiting

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

NCT07174310Parkinson's Disease

DrugPrasinezumab

Hoffmann-La Roche

Phase 3

900

Kogarah, Westmead, Woolloongabba, Clayton, Parkville, Prahan, Nedlands

2025-11-24

Active, closed

A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

NCT07217015Atopic Dermatitis

DrugKT-621

Kymera Therapeutics, Inc.

Phase 2

200

Darlinghurst, Kogarah, Brisbane, Woolloongabba, Melbourne

2025-11-24

Recruiting

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

NCT07149857Multiple Myeloma

DrugsCilta-cel·Fludarabine·Cyclophosphamide

Janssen Research & Development, LLC

Phase 2

Camperdown, Clayton, Heidelberg, Murdoch, Woolloongabba

2025-10-03

Recruiting

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

NCT07207811Transthyretin Amyloid Cardiomyopathy (ATTR CM)

DrugNNC6019-0001

Novo Nordisk A/S

Phase 3

1,280

Darlinghurst, Liverpool, Westmead, Woolloongabba, Adelaide, Hobart, Clayton, Melbourne

2025-10-02

Recruiting

Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors

NCT07110584Advanced Tumors

ModeX Therapeutics, An OPKO Health Company

Phase 1/2

235

Liverpool, Waratah, Woolloongabba

2025-10-01

Recruiting

Akyva First In Human

NCT06956209Underactive Bladder

Iota Biosciences, Inc

Not applicable

Woolloongabba, Melbourne N.

2025-09-24

Recruiting

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967Plaque Psoriasis

DrugsUstekinumab·Deucravacitinib

Bristol-Myers Squibb

Phase 3

3,040

Darlinghurst, Kogarah, Westmead, Greenslopes, Woolloongabba, Carlton, Clayton, East Melbourne

2025-09-22

Recruiting

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

NCT06855771Carcinoma, Non-Small-Cell Lung

DrugsNavlimetostat·Iza-bren

Bristol-Myers Squibb

Phase 2

182

Campbelltown, Camperdown, Woolloongabba, Adelaide

2025-09-09

Recruiting

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT07164443Metastatic Castration-resistant Prostatic Neoplasms

DrugsJNJ-87189401·Pasritamig

Janssen Research & Development, LLC

Phase 3

1,203

Heidelberg, Kurralta Park, Melbourne, Murdoch, Woolloongabba

2025-09-02

Recruiting

A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa

NCT06628947Retinitis Pigmentosa

Kiora Pharmaceuticals, Inc.

Phase 2

Sydney, Woolloongabba, Adelaide, East Melbourne, Nedlands

2025-08-29

Recruiting

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

NCT06989359IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN)

ADARx Pharmaceuticals, Inc.

Phase 2

Liverpool, Wollongong, Sydney, Woolloongabba

2025-08-28

Recruiting

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.

NCT06925321Invasive Mold Infections

DrugFosmanogepix

Basilea Pharmaceutica

Phase 3

234

Clayton, Melbourne, Parkville, Westmead, Woolloongabba

2025-08-26

Recruiting

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

NCT06952803Prostate Cancer

DrugsPrednisolone/Prednisone·Saruparib·Abiraterone

AstraZeneca

Phase 3

700

Kingswood, Murdoch, Orange, South Brisbane, St Leonards, Waratah, Woolloongabba

2025-08-06

Recruiting

Study Evaluating the Efficacy and Safety of Artesunate

NCT06853184CMV Infection

DrugsGanciclovir·Artesunate

Amivas Inc.

Phase 2

Westmead, Woolloongabba

2025-08-01

Not yet open

Clinical Performance Study of Microbio InfectID-BSI for Detection of Bacteria and Yeast With Patient Blood Samples

NCT06531031Bloodstream Infection, Sepsis, Septic Shock

Microbio Co Ltd

Observational

1,500

Chermside, Woolloongabba

2025-08

Recruiting

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

NCT07037433Atherosclerotic Cardiovascular Disease, Overweight, Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

12,800

Charlestown, Darlinghurst, St Leonards, Auchenflower, Herston, Milton, Woolloongabba, Bedford Park

2025-07-25

Recruiting

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

NCT06758401Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)

DrugsSigvotatug vedotin·Pembrolizumab

Pfizer

Phase 3

714

Coffs Harbour, North Ryde, Sydney, Birtinya, Douglas, Gympie, Nambour, Woolloongabba

2025-07-23

Recruiting

Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

NCT06960395Solid Tumor Malignancies, EGFR Positive Solid Tumors, EGFR

DrugPembrolizumab

Vir Biotechnology, Inc.

Phase 1

450

Wollongong, Woolloongabba

2025-07-22

Recruiting

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

NCT06974110Advanced Solid Tumor, Metastatic Solid Tumor, Endometrial Cancer, MSI-H Cancer

DrugIrinotecan

MOMA Therapeutics

Phase 1

132

Sydney, Westmead, Woolloongabba, Adelaide, Clayton, Perth

2025-07-16

Recruiting

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

NCT07082803Lymphoma, Lymphoma, Non Hodgkin

DrugZeprumetostat

Treeline Biosciences, Inc.

Phase 1

180

Macquarie Park, Woolloongabba, Malvern, Melbourne, Perth

2025-06-23

Recruiting

A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

NCT06944522Parkinsons Disease (PD)

BlueRock Therapeutics

Phase 3

102

Randwick, Southport, Woolloongabba, Clayton, Melbourne, Parkville

2025-06-17

Recruiting

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

NCT06943872Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsSonrotoclax·Venclexta·Obinutuzumab·Venetoclax

BeOne Medicines

Phase 3

630

Blacktown, Kogarah, Lismore, North Ryde, St Leonards, Birtinya, Woolloongabba, Clayton

2025-06-11

Active, closed

An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis

NCT07027527Atopic Dermatitis

DrugsAPG777·Dupilumab

Apogee Therapeutics, Inc.

Phase 1

Darlinghurst, Kogarah, Westmead, Woolloongabba, Carlton, East Melbourne, Mitcham, Parkville

2025-06-04

Recruiting

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT06852222Leukemia, Myeloid, Acute

DrugsBleximenib·Azacitidine·Venetoclax

Janssen Research & Development, LLC

Phase 3

600

Bedford Park, Camperdown, Fitzroy, Kogarah, Melbourne, Woolloongabba

2025-06-04

Active, closed

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event

NCT07000123Cardiovascular Disease

DrugAZD0780

AstraZeneca

Phase 3

3,103

Coffs Harbour, Ipswich, Joondalup, Leabrook, Liverpool, Maroubra, Melbourne, Woolloongabba

2025-05-28

Recruiting

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative

DrugsSPY001·SPY002·SPY003

Spyre Therapeutics, Inc.

Phase 2

645

Murdoch, Concord, Heidelberg, Liverpool, Melbourne, South Brisbane, Woolloongabba

2025-05-27

Recruiting

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

NCT06563895Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies

DrugAcoramidis

Eidos Therapeutics, a BridgeBio company

Phase 3

587

Darlinghurst, Murdoch, Westmead, Woolloongabba

2025-05-12

Recruiting

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06935357Immunoglobulin A Nephropathy (IgAN)

DrugFelzartamab

Biogen

Phase 3

454

New Lambton, New South Wales, St Leonards, Westmead, Douglas, Herston, Southport, Woolloongabba

2025-05-08

Active, closed

ASCEND CSP IDE Study

NCT06830746Heart Failure, Ventricular Arrythmia

Abbott Medical Devices

Not applicable

414

Chermside, Woolloongabba, Adelaide, Clayton

2025-04-11

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

NCT06868277Carcinoma, Non-Small Cell Lung

DrugsRilvegostomig·Keytruda·Pembrolizumab

AstraZeneca

Phase 3

830

Hobart, Woolloongabba

2025-04-10

Recruiting

Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT07032662Chronic Inflammatory Demyelinating Polyneuropathy

Immunovant Sciences GmbH

Phase 2

162

Macquarie Park, Parkville, Woolloongabba

2025-03-18

Recruiting

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

NCT06819878Moderately to Severely Active Crohns Disease

DrugAfimkibart

Hoffmann-La Roche

Phase 3

600

Garran, Sydney, Herston, South Brisbane, Woolloongabba, Adelaide, Epping, Murdoch

2025-03-17

Recruiting

Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma

NCT06767306Melanoma Metastatic

Melanoma Institute Australia

Phase 2

129

Westmead, Wollstonecraft, Woolloongabba, Melbourne

2025-03-06

Recruiting

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

NCT06841055Non-small Cell Lung Cancer

DrugsPumitamig·Docetaxel

BioNTech SE

Phase 2

Liverpool, Woolloongabba, Adelaide, Hobart, Nedlands

2025-03-03

Recruiting

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

NCT06855498Hidradenitis Suppurativa (HS)

DrugPovorcitinib

Incyte Corporation

Phase 3

600

Charleston, Kogarah, Liverpool, Sydney, Woolloongabba, Melbourne, Fremantle, Westmead

2025-02-28

Recruiting

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

NCT06780137Small Cell Lung Cancer

DrugsGocatamig·Ifinatamab Deruxtecan·Durvalumab

Merck Sharp & Dohme LLC

Phase 1/2

327

Woolloongabba, Clayton

2025-02-27

Active, closed

FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06909825Metastatic Castration-resistant Prostate Cancer

DrugsFPI-2265·Olaparib

Fusion Pharmaceuticals Inc.

Phase 2

Macquarie Park, Woolloongabba, Kurralta Park, Melbourne

2025-02-26

Recruiting

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease

NCT06732180Parkinson Disease

Gain Therapeutics, Inc.

Phase 1

Darlinghurst, Kogarah, Westmead, Woolloongabba, Adelaide, Melbourne, Parkville

2025-02-21

Recruiting

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

NCT06618287Lung Cancer, Breast Cancer

DrugsPumitamig·Iza-bren·Osimertinib·Opdivo

Bristol-Myers Squibb

Phase 1/2

416

Liverpool, Woolloongabba, Melbourne, Subiaco

2025-02-04

Recruiting

Implementing Surgery School Prehabilitation Using Telehealth

NCT06631872Adults Waiting to Undergo Lung Cancer or Major Abdominal, Open or Video Assisted Cancer Surgery

University of Melbourne

Not applicable

515

New Lambton Heights, Waratah, Southport, Woolloongabba, Burnie, Launceston, Heidelberg, Melbourne

2025-01-22

Recruiting

A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

NCT06284317Non Small Cell Lung Cancer

ETOP IBCSG Partners Foundation

Phase 3

290

Camperdown, Penrith, St Leonards, Woolloongabba, Bedford Park, Hobart, Box Hill, Melbourne

2025-01-15

Recruiting

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

NCT06589596Advanced Solid Tumor

DrugBGB-58067

BeOne Medicines

Phase 1

525

Blacktown, Woolloongabba, Clayton, Heidelberg, Nedlands

2025-01-10

Active, closed

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

NCT06760637Breast Cancer

DrugsAtirmociclib·Ribociclib·Abemaciclib·Palbociclib

Pfizer

Phase 3

1,035

Douglas, Woolloongabba, Capel Sound, Melbourne, Parkville

2025-01-06

Recruiting

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

NCT06585410Cutaneous Squamous Cell Carcinoma (CSCC)

DrugCemiplimab

Regeneron Pharmaceuticals

Phase 3

369

Darlinghurst, Westmead, Woolloongabba, South Yarra, Fremantle

2025-01-02

Active, closed

A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine

NCT06619509Solid Tumours

Boehringer Ingelheim

Phase 2

Randwick, Woolloongabba

2024-12-30

Recruiting

A Study Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy.

NCT06701721Diabetic Macular Edema, Diabetic Retinopathy

DrugTHN391

Therini Bio Pty Ltd

Phase 1

Parramatta, Sydney, Westmead, Woolloongabba, Adelaide, Albans, Malvern

2024-12-20

Active, closed

A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy

NCT06742190Multifocal Motor Neuropathy (MMN), MMN

DrugsEmpasiprubart·Immunoglobulin·IVIG

argenx

Phase 3

154

Parkville, Southport, Sydney, Woolloongabba

2024-12-18

Recruiting

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

NCT05421858Candidemia, Candidiasis, Invasive

DrugsCaspofungin·Fosmanogepix·Fluconazole

Basilea Pharmaceutica

Phase 3

450

Sydney, Woolloongabba, Melbourne, Parkville, Clayton

2024-12-11

Active, closed

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

NCT06691984Metastatic Castration-resistant Prostate Cancer

DrugsXaluritamig·Cabazitaxel·Abiraterone·Enzalutamide

Amgen

Phase 3

707

Camperdown, North Ryde, Woolloongabba, Clayton, Melbourne, Murdoch

2024-12-09

Active, closed

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

NCT06685757Antibody-mediated Rejection

DrugFelzartamab

Biogen

Phase 3

132

Parkville VIC, Murdoch, Woolloongabba

2024-12-03

Recruiting

Study of Intralesional FLD-103 in Subjects With Basal Cell Carcinoma (BCC)

NCT07670858Nodular Basal Cell Carcinoma

Feldan Therapeutics

Phase 1

Phillip, Charlestown, Randwick, Waitara, Westcourt, Woolloongabba

2024-10-30

Active, closed

Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

NCT06492837Follicular Lymphoma

DrugsMosunetuzumab·Zanubrutinib

Fondazione Italiana Linfomi - ETS

Phase 2

Adelaide, Liverpool, Melbourne, Woolloongabba

2024-10-23

Recruiting

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

NCT06623422Carcinoma, Non-Small-Cell Lung

DrugsIntismeran autogene·Pemetrexed·Gemcitabine·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

680

Waratah, Southport, Woolloongabba, Ballarat, Nedlands

2024-10-21

Active, closed

A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis

NCT06598462Eosinophilic Esophagitis (EoE)

DrugSolrikitug

Uniquity One (UNI)

Phase 2

184

Newcastle, Maroochydore, South Brisbane, Woolloongabba, Box Hill, Fitzroy, Parkville, Murdoch

2024-10-16

Recruiting

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

NCT06581432Solid Tumours

DrugZongertinib

Boehringer Ingelheim

Phase 2

588

Macquarie Park, St Leonards, Woolloongabba, Adelaide, Subiaco

2024-10-11

Active, closed

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

NCT06516965Prurigo Nodularis

DrugPovorcitinib

Incyte Corporation

Phase 3

346

Charlestown, Kogarah, Sydney, Westmead, Woolloongabba, Melbourne, Fremantle

2024-10-10

Recruiting

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

NCT06441747Cholangiocarcinoma

DrugsOlaparib·Durvalumab

Australasian Gastro-Intestinal Trials Group

Phase 2

Camperdown, Clayton, St Leonards, Westmead, Wollongong, Woolloongabba, Bedford Park, Melbourne

2024-09-23

Active, closed

To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

NCT06553027Parkinson Disease

Cerevance

Phase 3

330

Darlinghurst, Kogarah, Sydney, Woolloongabba, Cheltenham, Melbourne, Nedlands

2024-09-20

Recruiting

Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)

NCT06226805Acute Ischemic Stroke

Basking Biosciences, Inc.

Phase 2

228

New Lambton Heights, Woolloongabba, Adelaide, Clayton, Parkville, Murdoch

2024-07-31

Active, closed

A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)

NCT06455202Chronic Spontaneous Urticaria

DrugBarzolvolimab

Celldex Therapeutics

Phase 3

976

Charlestown, Darlinghurst, Kogarah, Westmead, Brisbane, Coorparoo, Woolloongabba, Box Hill

2024-07-19

Recruiting

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

NCT06252649Metastatic Colorectal Cancer

DrugsBevacizumab-awwb·Lumakras·Mvasi·Sotorasib

Amgen

Phase 3

450

Camperdown, Toowoomba, Woolloongabba, Bedford Park, Woodville South, Heidelberg

2024-07-17

Recruiting

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen

DrugIvosidenib

Servier Bio-Innovation LLC

Phase 3

136

Bedford Park, Camperdown, Fitzroy, Nedlands, Woolloongabba

2024-07-09

Recruiting

A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC

NCT06478693Hepatocellular Carcinoma

DrugsAtezolizumab·Bevacizumab

Myeloid Therapeutics

Phase 1

Sydney, Woolloongabba, Melbourne, Murdoch

2024-07-01

Active, closed

A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

NCT06015737Cutaneous Lupus Erythematosus

AstraZeneca

Phase 3

339

Kogarah, Melbourne, Mitcham, Westmead, Woolloongabba

2024-06-29

Active, closed

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06468228Hidradenitis Suppurativa

DrugLutikizumab

AbbVie

Phase 3

1,400

Phillip, Darlinghurst, Kogarah, Woolloongabba, East Melbourne

2024-06-27

Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

NCT06112314Advanced Melanoma

DrugsBrenetafusp·Relatlimab·Opdivo·Nivolumab

Immunocore Ltd

Phase 3

680

Waratah, Greenslopes, Nedlands, Heidelberg, North Melbourne, Wollstonecraft, Woolloongabba

2024-06-05

Recruiting

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

NCT06203210Small Cell Lung Cancer

DrugsAmrubicin·Ifinatamab Deruxtecan·Lurbinectedin·Topotecan

Daiichi Sankyo

Phase 3

540

Ballarat, Bedford Park, Camperdown, St Albans, Subiaco, Townsville, Woolloongabba

2024-05-21

Active, closed

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06158841Multiple Myeloma

DrugsElotuzumab·Etentamig·Carfilzomib·Selinexor

AbbVie

Phase 3

421

Kogarah, Liverpool, Waratah, Woolloongabba, Clayton, Fitzroy Melbourne, Melbourne

2024-05-19

Active, closed

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

NCT06407934Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 3

1,541

Westmead, Woolloongabba, Melbourne, Traralgon

2024-05-08

Active, closed

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

NCT06346067Advanced or Metastatic NRAS-mutant Melanoma

DrugsNaporafenib·Temodar·Dacarbazine·Trametinib

Erasca, Inc.

Phase 3

Waratah, Southport, Woolloongabba, Melbourne, Nedlands

2024-04-29

Recruiting

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

NCT05485961End Stage Kidney Disease

DrugClazakizumab

CSL Behring

Phase 2/3

3,110

Saint Leonards, Sydney, Cairns, Nambour, Woolloongabba, Clayton, St Albans, Bundaberg

2024-04-27

Recruiting

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

NCT06233942Advanced Solid Tumor

DrugsTislelizumab·Bevacizumab

BeOne Medicines

Phase 1

308

Blacktown, North Ryde, Wollongong, Woolloongabba, Clayton, Malvern, Melbourne, Nedlands

2024-04-12

Recruiting

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

NCT06330064Recurrent or Metastatic Solid Tumors

DrugIfinatamab Deruxtecan

Daiichi Sankyo

Phase 1/2

680

Blacktown, Mount Kuring-Gai, St Leonards, Woolloongabba, Subiaco

2024-04-10

Recruiting

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne

NCT06316297Acne

DrugAcne mRNA vaccine

Sanofi Pasteur, a Sanofi Company

Phase 1/2

800

Phillip, Kotara, Sydney, Waitara, Woolloongabba, Carlton, Melbourne

2024-04-05

Recruiting

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion

NCT06158854Immunoglobulin Light Chain (AL) Amyloidosis

DrugEtentamig

AbbVie

Phase 1/2

Westmead, Woolloongabba, Box Hill

2024-04-01

Active, closed

Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06290934Ulcerative Colitis

Gilead Sciences

Phase 2

228

Sydney, South Brisbane, Woolloongabba, Woodville, Clayton, Epping, Fitzroy, Footscray

2024-03-27

Recruiting

Radiation OmisSion in PAtients With CLinically Node Negative Breast Cancer Undergoing Lumpectomy

NCT05866458Breast Cancer

Ontario Clinical Oncology Group (OCOG)

Observational

352

Cudgen, Liverpool, North Sydney, Westmead, Herston, Woolloongabba, Bentleigh East, East Melbourne

2024-03-12

Active, closed

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

NCT06257264Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer

DrugsBGB-43395·Fulvestrant

BeiGene

Phase 1

103

Blacktown, Darlinghurst, Kingswood, St Leonards, Woolloongabba, Adelaide, Clayton

2024-03-11

Recruiting

SNV1521 in Participants With Advanced Solid Tumors

NCT06220864Advanced Solid Tumor

DrugsDB-1310·Abiraterone·Darolutamide

Synnovation Therapeutics, Inc.

Phase 1

400

Randwick, Woolloongabba, Clayton, Melbourne, Crawley

2024-02-23

Active, closed

ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function

NCT05907096Delayed Graft Function

DrugEmpasiprubart

argenx

Phase 2

103

Adelaide, Clayton, Woolloongabba

2024-02-17

Active, closed

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

NCT06230224B-Cell Non-Hodgkin Lymphoma (B-NHL)

DrugsOdronextamab·Ifosfamide·Paraplatin·Cytarabine

Regeneron Pharmaceuticals

Phase 3

216

Woolloongabba, Heidelberg

2024-02-15

Active, closed

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

NCT06151574Lung Cancer, Non-squamous, Non-small Cell

DrugsZongertinib·Pemetrexed·Keytruda·Cisplatin

Boehringer Ingelheim

Phase 3

428

Randwick, St Leonards, Woolloongabba, Heidelberg, Subiaco

2024-02-09

Active, closed

Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin)

NCT05860881Solid Organ Transplant Recipients, Skin Cancer

DrugsRapamycin·Sirolimus

Melanoma and Skin Cancer Trials Limited

Phase 3

146

Camperdown, Westmead, Chermside, Woolloongabba, Carlton, Melbourne

2024-02-09

Active, closed

T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma

NCT06157541Glioblastoma Multiforme, Astrocytoma, Grade IV

DrugsKeytruda·Pembrolizumab

Queensland Institute of Medical Research

Phase 1/2

Bowen Hills, Herston, Woolloongabba, Heidelberg

2024-02-08

Active, closed

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

NCT06191744Follicular Lymphoma (FL)

DrugsEpcoritamab·Bendamustine·Obinutuzumab·Vincristine

Genmab

Phase 3

1,095

Camperdown, Liverpool, Melbourne, Westmead, Douglas, Herston, Woolloongabba, Frankston

2024-02-05

Active, closed

A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06212999Hidradenitis Suppurativa (HS)

DrugPovorcitinib

Incyte Corporation

Phase 3

617

Charlestown, Kogarah, Liverpool, Woolloongabba, Carlton, Melbourne

2024-01-30

Active, closed

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

NCT06141486Multiple Sclerosis

DrugFrexalimab

Sanofi

Phase 3

943

Saint Leonards, Woolloongabba, Melbourne

2023-12-27

Recruiting

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

NCT06056830Prostate Cancer, Prostatic Neoplasms

Drug64Cu-SAR-bisPSMA

Clarity Pharmaceuticals Ltd

Phase 3

383

Sydney, Woolloongabba, Murdoch, Nedlands

2023-12-21

Recruiting

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

NCT06128629Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

DrugNexiguran ziclumeran

Intellia Therapeutics

Phase 3

1,200

Garran, Westmead, Cairns, Box Hill, Perth, Adelaide, Melbourne, Woolloongabba

2023-12-13

Recruiting

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

NCT06253130Advanced Solid Tumor

Eikon Therapeutics

Phase 1/2

156

Randwick, South Brisbane, Southport, Sydney, Woolloongabba, Frankston

2023-12-11

Active, closed

A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines

NCT05976243Chronic Inducible Urticaria

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

362

Woolloongabba, Carlton, Melbourne

2023-12-07

Active, closed

Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06029972Ulcerative Colitis

Gilead Sciences

Phase 2

176

Birtinya, South Brisbane, Woolloongabba, Adelaide, Woodville, Epping, Murdoch

2023-12-05

Active, closed

A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy

NCT05988073Multifocal Motor Neuropathy

argenx

Observational

413

Parkville, Southport, Woolloongabba

2023-11-29

Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

NCT05920356Non-Small Cell Lung Cancer (NSCLC)

DrugsSotorasib·Pembrolizumab

Amgen

Phase 3

750

Campbelltown, Concord, Kingswood, Port Macquarie, St Leonards, Waratah, Toowoomba, Woolloongabba

2023-11-16

Active, closed

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT06136741Moderate to Severe Atopic Dermatitis

DrugRezpegaldesleukin

Nektar Therapeutics

Phase 2

396

Darlinghurst, Kogarah, Westmead, Woolloongabba, Campbelltown, East Melbourne, Melbourne

2023-11-15

Active, closed

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

NCT06073821CLL

DrugsSonrotoclax·Zanubrutinib·Obinutuzumab·Venetoclax

BeOne Medicines

Phase 3

652

Concord, St Leonards, Benowa, Birtinya, Woolloongabba, Bedford PK, Clayton, Fitzroy

2023-11-11

Active, closed

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

NCT06072183Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo

DrugRitlecitinib

Pfizer

Phase 3

1,571

Phillip, Kogarah, St Leonards, Woolloongabba, Campbelltown, Woodville South, East Melbourne, Melbourne

2023-11-08

Active, closed

A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia

NCT05952037Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory

DrugsSonrotoclax·Zanubrutinib

BeOne Medicines

Phase 2

114

Concord, St Leonards, Woolloongabba, Bedford PK, Clayton, Fitzroy, Nedlands, Perth

2023-10-23

Recruiting

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

NCT06022029Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin

DrugCemiplimab

OncoNano Medicine, Inc.

Phase 1

168

Darlinghurst, Wollongong, Buderim, Southport, Woolloongabba, Bedford Park, Subiaco

2023-10-13

Recruiting

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

NCT06012240Alopecia Areata

DrugUpadacitinib

AbbVie

Phase 3

1,500

Darlinghurst, Kogarah, Coorparoo, Woolloongabba, Carlton, East Melbourne, Parkville, Fremantle

2023-10-11

Active, closed

A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma

NCT05888844Cutaneous Squamous Cell Carcinoma

DrugINCB099280

Incyte Corporation

Phase 2

Albury, Townsville, Woolloongabba, Box Hill, Clayton

2023-10-09

Active, closed

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

NCT06047080Large B-Cell Lymphoma

DrugsPolatuzumab Vedotin·Glofitamab·Doxorubicin·Prednisone

Hoffmann-La Roche

Phase 3

1,130

Concord, Randwick, Douglas, Woolloongabba, Bedford Park, Hobart, Box Hill, Fitzroy

2023-09-18

Recruiting

Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

NCT05722938Community-acquired Pneumonia

Biotest

Phase 3

590

Woolloongabba, Clayton, Footscray, Heidelberg, Saint Albans, Nedlands

2023-09-09

Recruiting

A Study of INI-822 in Healthy Volunteers and Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) or Presumed MASH

NCT05945537Metabolic Dysfunction-Associated Steatohepatitis

Inipharm Australia Pty Ltd

Phase 1

168

Camperdown, Campbelltown, Newcastle, Saint Leonards, Woolloongabba, Birtinya, Bedford Park, Box Hill

2023-09-08

Active, closed

Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma

NCT05864742Mantle Cell Lymphoma Refractory

DrugsNavitoclax·Ibrutinib·Venclexta·Venetoclax

Peter MacCallum Cancer Centre, Australia

Phase 2

Woolloongabba, Bedford Park, Parkville

2023-09-07

Recruiting

A Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Simultaneous Kidney Pancreas Transplant Recipients

NCT05325008BK Viremia, Kidney Transplant Infection, Kidney Transplant Failure and Rejection

DrugImmunoglobulin

The University of Queensland

Phase 3

280

Canberra, New Lambton Heights, Randwick, Sydney, Westmead, Brisbane, Townsville, Woolloongabba

2023-08-18

Recruiting

A Personalised Approach Utilising the Frailty Index to Empower Consumers

NCT05292989Gastrointestinal Diseases

Princess Alexandra Hospital, Brisbane, Australia

Not applicable

200

Woolloongabba

2023-08-14

Active, closed

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

NCT05797610Primary IgA Nephropathy

Hoffmann-La Roche

Phase 3

459

Kingswood, Kogarah, Liverpool, Woolloongabba, Adelaide, Parkville, St Albans

2023-08-08

Active, closed

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

NCT05607550Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations

DrugFurmonertinib

ArriVent BioPharma, Inc.

Phase 3

398

Heidelberg, Blacktown, St Leonards, Woolloongabba

2023-06-01

Recruiting

A Practice Change for Patients With Severe Chronic, Clinically Unexplained Gastrointestinal Symptoms

NCT05274854Gastrointestinal Diseases, Irritable Bowel Syndrome

The University of Queensland

Not applicable

200

Woolloongabba

2023-05-01

Recruiting

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

NCT05818683Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer

DrugsJNJ-101556143·Lutetium Lu 177 vipivotide tetraxetan·Pasritamig·Cabazitaxel

Janssen Research & Development, LLC

Phase 1

300

Kurralta Park, Macquarie University, Melbourne, Woolloongabba

2023-04-26

By invitation

A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT05735483Atopic Dermatitis, Eczema

DrugLebrikizumab

Eli Lilly and Company

Phase 3

333

Randwick, Westmead, Coorparoo, Woolloongabba

2023-03-09

Active, closed

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

14,012

Garran, Camperdown, Concord, Auchenflower, Sippy Downs, Woolloongabba, Adelaide, Leabrook

2023-03-09

Active, closed

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

NCT05654623Advanced Breast Cancer

DrugsVepdegestrant·Fulvestrant

Pfizer

Phase 3

624

Coffs Harbour, Birtinya, Woolloongabba, Kurralta Park, Hobart, Brighton, Geelong, Malvern

2023-03-03

Recruiting

LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology

NCT05184790Arrhythmias, Cardiac, Breast Cancer, Prostatic Cancer, Brain Cancer

University of Sydney

Observational

300

Saint Leonards, Woolloongabba, Melbourne

2023-02-28

Active, closed

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

NCT05555732Metastatic Non Small Cell Lung Cancer

DrugsDatopotamab deruxtecan·Pemetrexed·Keytruda·Cisplatin

Daiichi Sankyo

Phase 3

1,170

Adelaide, Bedford Park, Frankston, Kogarah, Wollongong, Woolloongabba

2023-01-11

Recruiting

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

NCT05549297Advanced Melanoma

DrugTebentafusp

Immunocore Ltd

Phase 3

540

Wollstonecraft, Greenslopes, Woolloongabba, Melbourne

2022-12-19

Active, closed

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

NCT05681351Severe Hypertriglyceridemia

DrugOlezarsen

Ionis Pharmaceuticals, Inc.

Phase 3

885

Saint Leonards, Adelaide, Camperdown, Clayton, Woolloongabba

2022-12-13

Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

NCT05633654Triple Negative Breast Cancer

DrugsSacituzumab Govitecan·Capecitabine·Pembrolizumab

Gilead Sciences

Phase 3

1,514

Campbelltown, Darlinghurst, Gateshead, Port Macquarie, Cairns, Douglass, Woolloongabba, Adelaide

2022-12-12

Active, closed

Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial

NCT05556720HIV, Organ Transplantation, Lymphoma, Non-Hodgkin, Chronic Lymphocytic Leukemia

DrugSpikevax

Monash University

Phase 3

960

Darlinghurst, Randwick, Westmead, Herston, Woolloongabba, Adelaide, Clayton, Fitzroy

2022-12-01

By invitation

An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

NCT05667493Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

DrugEplontersen

Ionis Pharmaceuticals, Inc.

Phase 3

1,400

Joondalup, Murdoch, Clayton, Hobart, Leabrook, Liverpool, Westmead, Woolloongabba

2022-11-30

Recruiting

Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)

NCT04939935Autosomal Dominant Polycystic Kidney Disease

DrugMetformin

The University of Queensland

Phase 3

1,174

Gosford, Sydney, Bundaberg, Douglas, Herston, Woolloongabba, Adelaide, Melbourne

2022-11-29

Active, closed

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

NCT05544552Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma

DrugTYRA-300

Tyra Biosciences, Inc

Phase 1/2

310

Macquarie Park, Southport, Woolloongabba, Heidelberg, Melbourne, Nedlands

2022-11-22

Active, closed

Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

NCT05583227Eosinophilic Esophagitis

DrugTezepelumab

AstraZeneca

Phase 3

368

Elizabeth Vale, Kogarah, South Brisbane, Woolloongabba

2022-11-10

Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

NCT05552222Multiple Myeloma

DrugsTalquetamab·Teclistamab·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 3

1,590

Camperdown, Geelong, Liverpool, Nedlands, New South Wales, Wollongong, Woolloongabba

2022-10-25

Recruiting

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

NCT05253651Colorectal Neoplasms

DrugsTucatinib·Erbitux·Herceptin·Avastin

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

400

Camperdown, Woolloongabba, Fitzroy

2022-10-24

Active, closed

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT05559359Atopic Dermatitis, Eczema

DrugLebrikizumab

Eli Lilly and Company

Phase 3

377

Coorparoo, Randwick, Westmead, Woolloongabba

2022-10-18

Recruiting

Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy

NCT05169177Liver Neoplasm

University of Sydney

Observational

Waratah, Westmead, Woolloongabba, Melbourne

2022-10-17

Active, closed

The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

NCT05540327Systemic Lupus Erythematosus

DrugEnpatoran

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 2

379

Clayton, Woolloongabba

2022-09-16

Active, closed

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

NCT05492578Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 2/3

1,856

Westmead, Woolloongabba, Carlton, Melbourne, Parkville, Traralgon

2022-08-22

Active, closed

A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition

NCT05061134Melanoma

DrugsCeralasertib·Durvalumab

AstraZeneca

Phase 2

194

Darlinghurst, East Melbourne, Herston, Woolloongabba

2022-08-11

Active, closed

A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer

NCT05388669Advanced or Metastatic Non-small Cell Lung Cancer

DrugsLazertinib·Amivantamab

Janssen Research & Development, LLC

Phase 3

418

Adelaide, Camperdown, Melbourne, Murdoch, Westmead, Woolloongabba

2022-08-05

Active, closed

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382286Triple Negative Breast Cancer, PD-L1 Positive

DrugsAbraxane·Sacituzumab Govitecan·Taxol·Nab-paclitaxel

Gilead Sciences

Phase 3

443

Albury, Kogarah, North Sydney, St Leonards, South Brisbane, Woolloongabba, Adelaide, Hobart

2022-07-25

Active, closed

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382299Triple Negative Breast Cancer, PD-L1 Negative

DrugsAbraxane·Sacituzumab Govitecan·Nab-paclitaxel·Gemcitabine

Gilead Sciences

Phase 3

623

Kogarah, South Brisbane, Woolloongabba, Adelaide, Clayton, Melbourne, Nedlands

2022-07-20

Active, closed

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

NCT05338970Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion

DrugPatritumab deruxtecan

Daiichi Sankyo

Phase 3

586

Camperdown, Kogarah, Liverpool, Melbourne, Subiaco, Woolloongabba

2022-07-08

Recruiting

Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma

NCT05025813Cutaneous Squamous Cell Carcinoma of the Head and Neck, Head and Neck Cancer

DrugPembrolizumab

Queensland Health

Phase 2

Camperdown, Herston, Woolloongabba

2022-06-28

Active, closed

Merit WRAPSODY™ Endoprosthesis for Treatment of Stenosis or Occlusion (WRAP)

NCT05062291Venous Stenosis, Venous Occlusion

Merit Medical Systems, Inc.

Observational

500

Clayton, Liverpool, Murdoch, Nedlands, Woolloongabba

2022-06-23

Recruiting

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

NCT05384626Locally Advanced Solid Tumor, Metastatic Solid Tumor

DrugsNeladalkib·Repaglinide·Itraconazole·Midazolam

Nuvalent Inc.

Phase 1/2

840

Sydney, Woolloongabba, Melbourne

2022-06-09

Active, closed

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

NCT05270044Melanoma

Pierre Fabre Medicament

Phase 3

815

Sydney, Wollstonecraft, Woolloongabba, North Adelaide, Box Hill, Heidelberg, Prahran, Nedlands

2022-05-02

Active, closed

Early Rehabilitation in Patients on Extracorporeal Membrane Oxygenation

NCT05003609Extracorporeal Membrane Oxygenation Complication

Australian and New Zealand Intensive Care Research Centre

Not applicable

100

Camperdown, Darlinghurst, Chermside, Woolloongabba, Melbourne, Murdoch

2022-04-27

Active, closed

A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

NCT05288166Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs

DrugsAbiraterone·Abemaciclib·Prednisolone·Prednisone

Eli Lilly and Company

Phase 3

925

Camperdown, Coffs Harbour, Darlinghurst, Liverpool, Macquarie University, South Brisbane, Southport, Woolloongabba

2022-04-14

Active, closed

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

NCT05317416Multiple Myeloma

DrugsElranatamab·Lenalidomide

Pfizer

Phase 3

854

Camperdown, Nowra, Westmead, Wollongong, Benowa, Clayfield, Woolloongabba, East Melbourne

2022-03-25

Recruiting

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT05091424Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

DrugsMosunetuzumab·Venclyxto·Venclexta·Tocilizumab

Hoffmann-La Roche

Phase 1

332

Woolloongabba, East Melbourne, Melbourne

2022-03-07

Active, closed

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

NCT05139602Hidradenitis Suppurativa

DrugLutikizumab

AbbVie

Phase 2

210

Phillip, Darlinghurst, Kogarah, Woolloongabba

2021-12-28

Active, closed

Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer

NCT04905069Prostate Cancer

Boston Scientific Corporation

Not applicable

500

Waratah, Woolloongabba, Nedlands

2021-12-21

Recruiting

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

NCT04910685Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis

Blueprint Medicines Corporation

Phase 2/3

534

Woolloongabba, Melbourne

2021-11-30

Recruiting

Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation Stroke

NCT05105633Basilar Artery Occlusion

DrugTenecteplase

University of Melbourne

Phase 2/3

688

Bankstown, Newcastle, Sydney, Gold Coast, Woolloongabba, Adelaide, Melbourne, Murdoch

2021-11-29

Active, closed

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

NCT05030428Atherosclerotic Cardiovascular Disease

DrugInclisiran sodium

Novartis Pharmaceuticals

Phase 3

17,004

Botany, New Lambton Heights, Auchenflower, Milton, Woolloongabba, Adelaide, Bedford Park, Leabrook

2021-11-23

Active, closed

A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis

NCT05081557Atopic Dermatitis

AbbVie

Observational

873

Miranda, Woolloongabba, Bedford Park, East Melbourne, Victoria Park, Newtown

2021-11-17

Active, closed

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

NCT04994717Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)

DrugBlinatumomab

Amgen

Phase 3

303

Garran, Camperdown, Liverpool, St Leonards, Westmead, Herston, Woolloongabba, Adelaide

2021-11-02

Recruiting

The CARMA Technique Study

NCT05099432Colonic Polyp, Colonic Sessile Serrated Lesion

Princess Alexandra Hospital, Brisbane, Australia

Not applicable

Woolloongabba

2021-11

Active, closed

Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

NCT04988386Amyloid Cardiomyopathy, Transthyretin-Related

DrugAcoramidis

Eidos Therapeutics, a BridgeBio company

Phase 3

389

Darlinghurst, Woolloongabba, Adelaide, Hobart, Box Hill, Murdoch

2021-10-27

Active, closed

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

NCT04712097Relapsed or Refractory Follicular Lymphoma

DrugsMosunetuzumab·Lenalidomide·Rituximab

Hoffmann-La Roche

Phase 3

478

Waratah, Woolloongabba, Adelaide, Geelong

2021-10-27

Active, closed

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

NCT04975308Breast Neoplasms, Neoplasm Metastasis

DrugsImlunestrant·Exemestane·Abemaciclib·Fulvestrant

Eli Lilly and Company

Phase 3

874

Darlinghurst, Woolloongabba, Kurralta Park, Box Hill, Melbourne

2021-10-04

Recruiting

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

NCT05020236Multiple Myeloma

DrugsDarzalex·Elranatamab·Pomalidomide·Daratumumab

Pfizer

Phase 3

893

Benowa, Clayfield, Greenslopes, Woolloongabba, East Melbourne, Fitzroy, Geelong, Melbourne

2021-10-04

Active, closed

Study of INBRX-109 in Conventional Chondrosarcoma

NCT04950075Conventional Chondrosarcoma

DrugINBRX-109

Inhibrx Biosciences, Inc

Phase 2

206

Adelaide, Camperdown, Woolloongabba

2021-09-23

Active, closed

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

NCT04557462Primary IgA Nephropathy

DrugIptacopan

Novartis Pharmaceuticals

Phase 3

448

Woolloongabba, Adelaide, Parkville

2021-09-20

Recruiting

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma

DrugTacabrutideg

BeOne Medicines

Phase 1/2

645

Concord, Waratah, Woolloongabba, Fitzroy, Heidelberg, Melbourne, Nedlands, West Perth

2021-09-13

Active, closed

A Study of AL102 in Patients With Progressing Desmoid Tumors

NCT04871282Desmoid, Desmoid Tumor

Immunome, Inc.

Phase 2/3

198

Camperdown, Woolloongabba, Kurralta Park, Melbourne

2021-09-01

Active, closed

A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

NCT04657289Neovascular Age-related Macular Degeneration (nAMD)

DrugRanibizumab

Hoffmann-La Roche

Phase 3

451

Albury, Hurstville, Liverpool, Miranda, Sydney, Woolloongabba, East Melbourne, Rowville

2021-07-14

Active, closed

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

NCT04908202Psoriatic Arthritis

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

670

Phillip, Botany, Westmead, Woolloongabba, Hobart, Camberwell

2021-07-13

Active, closed

Evaluation of TAVR Using the NAVITOR Valve in a Global Investigation

NCT04788888Symptomatic Severe Aortic Stenosis

Abbott Medical Devices

Not applicable

434

Murdoch, Sydney, Woolloongabba, Adelaide, Melbourne, Ryde

2021-07-13

Active, closed

Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA

NCT04319783Advanced Prostate Carcinoma, Cancer of Prostate, PSA, Castrate Resistant Prostate Cancer

DrugDarolutamide

Trans Tasman Radiation Oncology Group

Phase 2

Darlinghurst, Hurstville, Saint Leonards, Waratah, Herston, Raymond Terrace, Woolloongabba, Adelaide

2021-06-02

Active, closed

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

NCT04873362Breast Cancer

DrugsTrastuzumab emtansine·Herceptin·Tecentriq·Trastuzumab

Hoffmann-La Roche

Phase 3

1,188

Campbelltown, St Leonards, Woolloongabba

2021-05-04

Recruiting

A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis

NCT04772079Plaque Psoriasis

DrugDeucravacitinib

Bristol-Myers Squibb

Phase 3

153

Darlinghurst, Westmead, Brisbane, Woolloongabba, Clayton, Melbourne

2021-03-23

Active, closed

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

NCT04685135Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer

DrugsAdagrasib·Taxotere·Docetaxel

Mirati Therapeutics Inc.

Phase 3

453

Mackay, Bedford Park, Clayton, Douglas, St Leonards, Tweed Heads, Wollongong, Woolloongabba

2021-02-23

Active, closed

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

NCT04619004Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

DrugPatritumab deruxtecan

Daiichi Sankyo

Phase 2

277

Blacktown, Camperdown, Kogarah, Melbourne, Subiaco, Woolloongabba

2021-02-02

Recruiting

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

NCT04031677Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

250

Woolloongabba, Melbourne, Camperdown

2021-01-20

Active, closed

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

NCT04589845Solid Tumors

DrugsCamonsertib·Belvarafenib·Pralsetinib·Divarasib

Hoffmann-La Roche

Phase 2

920

Darlinghurst, Woolloongabba, Melbourne, Parkville

2021-01-18

Active, closed

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

NCT04607421Neoplasms

DrugsEncorafenib·Leucovorin·Irinotecan·Adrucil

Pfizer

Phase 3

841

Camperdown, Liverpool, St Leonards, Herston, Woolloongabba, Adelaide, Clayton, Heidelberg

2020-12-21

Recruiting

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

NCT04613596Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer

DrugsAdagrasib·Pembrolizumab

Mirati Therapeutics Inc.

Phase 2/3

626

Ballarat, Bedford Park, Clayton, Garran, Hyde Park, Port Macquarie, Wollongong, Woolloongabba

2020-12-02

Active, closed

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

NCT04512235AL Amyloidosis

DrugsAnselamimab·Cyclophosphamide, bortezomib, and dexamethasone (CyBorD)

Alexion Pharmaceuticals, Inc.

Phase 3

281

Box Hill, Murdoch, Westmead, Woolloongabba

2020-11-03

Active, closed

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

NCT04544449Multiple Sclerosis, Primary Progressive

DrugsFenebrutinib·Ocrelizumab

Hoffmann-La Roche

Phase 3

985

Camperdown, Liverpool, New Lambton, Woolloongabba, Box Hill, Heidelberg, Parkville

2020-10-26

Active, closed

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

NCT04546009Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

DrugsGiredestrant·Palbociclib·Letrozole

Hoffmann-La Roche

Phase 3

992

Waratah, South Brisbane, Woolloongabba, Melbourne, St Albans, Murdoch

2020-10-09

Active, closed

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT04487080Carcinoma, Non-Small-Cell Lung

DrugsLazertinib·Amivantamab·Osimertinib

Janssen Research & Development, LLC

Phase 3

1,074

Bedford Park, Heidelberg, Malvern, Murdoch, Nedlands, Westmead, Wollongong, Woolloongabba

2020-09-30

Active, closed

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

NCT04416984Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma

DrugsALLO-647·Fludarabine·Cyclophosphamide

Allogene Therapeutics

Phase 1/2

160

Woolloongabba, Clayton, Fitzroy

2020-05-21

Recruiting

Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

NCT04310930Pulmonary Disease Due to Mycobacteria (Diagnosis)

DrugsImipenem·Tigecycline·Amikacin·Clofazimine

The University of Queensland

Phase 2/3

300

Kogarah, South Brisbane, Woolloongabba, Heidelberg, Parkville, Perth, Adelaide, Birtinya

2020-03-02

Active, closed

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

NCT04191499Breast Cancer

DrugsInavolisib·Palbociclib·Fulvestrant

Hoffmann-La Roche

Phase 2/3

325

Macquarie Park, Wollongong, South Brisbane, Woolloongabba, Fitzroy, Frankston

2020-01-29

Active, closed

Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM)

NCT02984566Liver Cancer

University of Sydney

Not applicable

Penrith, Westmead, Woolloongabba, Melbourne

2020-01-14

Active, closed

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

NCT04129502Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

DrugsMobocertinib·Pemetrexed·Cisplatin·Carboplatin

Takeda

Phase 3

354

St Leonards, Woolloongabba, Bedford Park

2020-01-10

Active, closed

MAnagement of Systolic Blood Pressure During Thrombectomy by Endovascular Route for Acute Ischaemic STROKE

NCT05645861Stroke, Embolus Cerebral, Blood Pressure

Auckland City Hospital

Not applicable

550

Sydney, Southport, Woolloongabba

2019-11-28

Active, closed

HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT04153149Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

DrugVutrisiran

Alnylam Pharmaceuticals

Phase 3

655

Darlinghurst, Northmead, Woolloongabba, Adelaide, Melbourne

2019-11-26

Recruiting

Abbott DBS Post-Market Study of Outcomes for Indications Over Time

NCT04071847Movement Disorders, Parkinson Disease, Essential Tremor, Tremor

Abbott Medical Devices

Observational

1,000

Woolloongabba, Parkville

2019-11-26

Active, closed

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT04033445Ulcerative Colitis

DrugGuselkumab

Janssen Research & Development, LLC

Phase 2/3

1,064

Camberwell, Clayton, Footscray, Murdoch, Perth, South Brisbane, Subiaco, Woolloongabba

2019-09-26

By invitation

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

NCT03683186PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension

United Therapeutics

Phase 3

1,000

Camperdown, Darlinghurst, Sydney, Chermside, Woolloongabba, Hobart, Fitzroy, Melbourne

2019-09-23

Recruiting

Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)

NCT03340129Melanoma Stage Iv

DrugsYervoy·Opdivo·Ipilimumab·Nivolumab

Melanoma Institute Australia

Phase 2

218

Sydney, Waratah, Wollstonecraft, Woolloongabba, Adelaide, East Melbourne, Melbourne, Perth

2019-08-14

Active, closed

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

NCT04008030Metastatic Colorectal Cancer

DrugsLeucovorin·Fluorouracil·Ipilimumab·Irinotecan

Bristol-Myers Squibb

Phase 3

839

Westmead, Woolloongabba, Elizabeth Vale, Clayton, Heidelberg

2019-08-05

Active, closed

An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

NCT03897881Melanoma

DrugsIntismeran autogene·Pembrolizumab

ModernaTX, Inc.

Phase 2

267

North Sydney, Westmead, Woolloongabba, Murdoch, Subiaco

2019-07-18

Recruiting

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

NCT03947385Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors

DrugsDarovasertib·Binimetinib·Crizotinib

IDEAYA Biosciences

Phase 1/2

336

Sydney, Woolloongabba

2019-06-28

Active, closed

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

NCT03937219Renal Cell Carcinoma

DrugsYervoy·Cabozantinib·Opdivo·Ipilimumab

Exelixis

Phase 3

855

Albury, Kogarah, North Ryde, Sydney, South Brisbane, Woolloongabba, Adelaide, North Adelaide

2019-06-25

Active, closed

Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)

NCT03992417Dermatitis Atopic

DrugDupilumab

Sanofi

Observational

955

Kogarah, Woolloongabba, Bedford Park, Carlton

2019-06-11

Active, closed

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

NCT03836261Chronic Lymphocytic Leukemia

DrugsVenclyxto·Acalabrutinib·Venclexta·Obinutuzumab

Acerta Pharma BV

Phase 3

984

Adelaide, Darlinghurst, Heidelberg, Kogarah, Melbourne, Nedlands, Waratah, Woolloongabba

2019-02-25

Active, closed

A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

NCT03673501Gastrointestinal Stromal Tumors

DrugsRipretinib·Sunitinib

Deciphera Pharmaceuticals, LLC

Phase 3

453

Albury, Randwick, Woolloongabba, Kurralta Park, Melbourne

2019-02-08

Active, closed

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

NCT03553836Melanoma

DrugsKeytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

976

North Sydney, Westmead, Cairns, Southport, Woolloongabba, Adelaide, Kurralta Park, Melbourne

2018-09-12

Active, closed

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

NCT03529110Breast Cancer

DrugsTrastuzumab emtansine·Trastuzumab deruxtecan

Daiichi Sankyo

Phase 3

524

Tweed Heads, Woolloongabba, Box Hill, Frankston, Melbourne, Subiaco

2018-08-09

Active, closed

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

NCT03568318Atopic Dermatitis

DrugUpadacitinib

AbbVie

Phase 3

1,533

Kogarah, St Leonards, Westmead, Woolloongabba, Fremantle

2018-08-09

Active, closed

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants

NCT03451851Psoriasis

DrugsEnbrel·Etanercept·Guselkumab

Janssen Research & Development, LLC

Phase 3

120

Box Hill, St Leonards, Woolloongabba

2018-07-11

Active, closed

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

NCT03212404Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Malignant Mesothelioma, Advanced

Checkpoint Therapeutics, Inc.

Phase 1

272

Wollongong, Benowa, Buderim, Greenslopes, South Brisbane, Woolloongabba, Box Hill, Malvern

2017-09-20

Active, closed

A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

NCT03148418Cancer

DrugsAvastin·Tecentriq·Atezolizumab·Bevacizumab

Hoffmann-La Roche

Phase 3

382

Camperdown, Woolloongabba

2017-09-20

Recruiting

International Registry for Men With Advanced Prostate Cancer (IRONMAN)

NCT03151629Prostate Cancer

Prostate Cancer Clinical Trials Consortium

Observational

5,000

Herston, Darlinghurst, Sydney, Cleveland, Woolloongabba, Box Hill, Melbourne, Mount Waverley

2017-07-21

Active, closed

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

NCT03229200Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell, Graft Vs Host Disease

DrugIbrutinib

Pharmacyclics Switzerland GmbH

Phase 4

297

Kogarah, Sydney, Woolloongabba, Bedford Park, Ballarat, Box Hill, Clayton, Fitzroy

2017-05-22

Active, closed

A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

NCT02993523Acute Myeloid Leukemia (AML)

DrugsAzacitidine·Venetoclax

AbbVie

Phase 3

443

Woolloongabba, Adelaide, Melbourne, Parkville, Nedlands, Perth

2017-02-02

Active, closed

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer

NCT02609776Non-Small-Cell Lung Cancer

DrugsLazertinib·Amivantamab·Pemetrexed·Carboplatin

Janssen Research & Development, LLC

Phase 1

751

Camperdown, Heidelberg, Kogarah, Murdoch, Woolloongabba

2016-05-24

Active, closed

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

NCT02511106Stage IB-IIIA Non-small Cell Lung Carcinoma

DrugOsimertinib

AstraZeneca

Phase 3

682

Bedford Park, Camperdown, Darlinghurst, Heidelberg, Kogarah, Kurralta Park, Woolloongabba

2015-10-21

Active, closed

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors

NCT02375204Germ Cell Tumor, Teratoma, Choriocarcinoma, Germinoma

DrugsPegylated G-CSF·G-Csf·Ifosfamide·CDDP

Alliance for Clinical Trials in Oncology

Phase 3

420

Camperdown, Woolloongabba, Box Hill, Melbourne

2015-08-06

Active, closed

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

NCT02246621Breast Cancer

DrugsAnastrozole·Abemaciclib·Letrozole

Eli Lilly and Company

Phase 3

493

Camperdown, Sydney, Wahroonga, South Brisbane, Woolloongabba, Woodville, Geelong, Murdoch

2014-11-06

Active, closed

Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases

NCT02374242Melanoma, Brain Metastases

DrugsYervoy·Opdivo·Ipilimumab·Nivolumab

Melanoma Institute Australia

Phase 2

Wollstonecraft, Woolloongabba, Adelaide, East Melbourne

2014-11-04

Active, closed

Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer

NCT02170090Cholangiocarcinoma, Gall Bladder Carcinoma

DrugsCapecitabine·Gemcitabine·Cisplatin

Universitätsklinikum Hamburg-Eppendorf

Phase 3

789

Bankstown, Kingswood, Kogarah, Randwick, Waratah, Douglas, Herston, Woolloongabba

2014-04

Recruiting

Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

NCT02582697Germ Cell Tumor

DrugsPegylated G-CSF·Filgrastim·Pegfilgrastim·Bleomycin

University of Sydney

Phase 3

500

Newcastle, St Leonards, Sydney, Wahroonga, Brisbane, South Brisbane, Woolloongabba, Adelaide

2014-02

Recruiting

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

NCT01522183Atypical Hemolytic-Uremic Syndrome

Alexion Pharmaceuticals, Inc.

Observational

3,000

Westmead, Cairns, Herston, Woolloongabba, Adelaide, Heidelberg, Parkville, Murdoch

2013-03-18

Active, closed

Psoriasis Longitudinal Assessment and Registry

NCT00508547Psoriasis

Janssen Scientific Affairs, LLC

Observational

20,167

Fremantle, Melbourne, Miranda, Sydney, Woolloongabba

2007-06-21

Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Australian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-australia/city/woolloongabba

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

Clinical Trials in Woolloongabba, 2026

Trials with a site in Woolloongabba

About this register

How many clinical trials are recruiting in Woolloongabba?

Summary by phase

Most active sponsors

Phase	Studies	Recruiting	Share
Phase 3	126	53	52.3%
Phase 2	44	21	18.3%
Phase 1	21	17	8.7%
Not applicable	14	7	5.8%
Phase 1/2	13	10	5.4%
Observational	12	6	5%
Phase 2/3	9	5	3.7%
Phase 4	2	1	0.8%